Search Videos and More
News
Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL
A Dana-Farber Cancer Institute investigator presented positive interim data from the BRUIN CLL-322 trial, the first randomized phase 3 data to be reported about a Bruton tyrosine kinase (BTK) inhibitor as part of a fixed-duration therapy in relapsed/refractory chronic lymphocytic leukemia.
News
ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial, a first-of-its-kind randomized trial of teclistamab, a BCMA-targeted bispecific antibody, in high-risk smoldering multiple myeloma.
News
Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2alpha inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.
Symposium
2026 American Association for Cancer Research
Review scientific findings and information presented by Dana-Farber physician-scientists at the 2026 AACR Annual Meeting in San Diego, CA, April 17-22, 2026
Symposium
2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Review scientific discoveries and information presented by Dana-Farber physician-scientists at the 2026 ASCO Annual Meeting in Chicago, IL, May 29 - June 2, 2026.
News
Staying One Step Ahead
New insights into how leukemia escapes treatment are shaping smarter combination therapies
News
ADC Provides Patients with Better Results Even After Subsequent Therapy for Advanced Triple-Negative Breast Cancer
A shift in the way advanced triple-negative breast cancer is treated may be on the horizon with mounting evidence that moving sacituzumab govitecan, an antibody-drug conjugate (ADC), to the first line of treatment confers long-term benefit compared to standard therapy, including continued benefit even after subsequent therapy.
News
Dana-Farber Research News 06.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 1 - 15.
News
Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death
High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.
News
RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.
News
Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma
For patients with relapsed or refractory multiple myeloma (RRMM), the addition of the oral drug mezigdomide to standard treatment with carfilzomib and dexamethasone markedly improved progression-free survival over standard treatment alone, according to results from a phase 3 clinical trial led by investigators at Dana-Farber Cancer Institute.
News
Dana-Farber Researchers to Present Two Plenary Studies and Additional Late-Breaking Cancer Research at 2026 ASCO
Dana-Farber Cancer Institute researchers will present findings at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) from several studies with compelling and potentially practice-changing results spanning multiple cancer types, including pancreatic, prostate, breast, and multiple myeloma.